Current regulatory news

Boston Scientific Corp. received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB); The U.S. Food and Drug Administration’s (FDA) gave 510(k) clearance for Getinge’s Vasoview Hemopro 3

FDA APPROVALS

AGENT Drug-Coated Balloon (DCB)
PHOTOS COURTESY OF RESPECTIVE COMPANIES

Boston Scientific Corp. received U.S. Food and Drug Administration (FDA) approval for the AGENT Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.

While the stenting of coronary lesions continues to show a substantial improvement in quality of life for patients with coronary artery disease, ISR still encompasses 10% of percutaneous coronary interventions in the U.S. Serving as an alternative to traditional therapies, additional layers of stenting or radiation, the AGENT DCB is a paclitaxel-coated balloon catheter that transfers a therapeutic dose of drug to the vessel wall to help prevent ISR reoccurrence.

Following Breakthrough Device Designation granted for the technology by the FDA in 2021, the approval was supported by positive results from the multicenter, prospective, randomized controlled AGENT IDE trial, which enrolled 600 patients at 40 U.S. sites. In the prespecified interim analysis of the first 480 patients enrolled, the study met the primary endpoint of target lesion failure (TLF) at 12 months with the AGENT DCB demonstrating statistical superiority to uncoated balloon angioplasty (17.9% vs. 28.7%; P=0.006). Findings also included zero definite/probable cases of clotting within the stent (0.0% vs. 3.9%, P=0.001), a 49% risk reduction in heart attack at the target vessel (6.4% vs. 12.3%, P=0.03), and low adverse event rates at 12 months.
https://www.bostonscientific.com

 


Vasoview Hemopro 3
The U.S. Food and Drug Administration’s (FDA) gave 510(k) clearance for Getinge’s Vasoview Hemopro 3, the latest addition to the medtech company’s endoscopic vessel harvesting (EVH) solutions. Designed with customer centricity top of mind, Vasoview Hemopro 3 is expected to offer enhanced procedural efficiency in healthcare.

 

The culmination of extensive market research and advisory boards conducted in partnership with clinicians within the EVH field, Vasoview Hemopro 3 represents collaborative innovation. Feedback from the studies has been central in shaping the product, focusing on improvements enhancing harvester efficiency and patient outcomes. Advancements include enhanced smoke evacuation, regulated energy control, ergonomic game controller style handle, and an integrated cable. 
https://www.getinge.com

May 2024
Explore the May 2024 Issue

Check out more from this issue and find your next story to read.